+2 more ↓
59%
Finnrick rating
#269 of 289 ranked vendors
42 of 75 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Skye Peptides has a split purity-focus record, with Semaglutide and Ipamorelin testing comparatively clean while BPC-157 and CJC-1295 are held down by repeated purity misses. Evidence is broad but dispersed: some newer results show recovery, yet batch-ID gaps, overfill history, and narrow same-batch coverage keep consistency uncertain.

methodology →
vendor intelligence report
Vendor Intelligence Report: Skye Peptides

We investigated who actually operates Skye Peptides — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

26 pages5 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Semaglutide
$13.39
82%
9
2
Tirzepatide
$9.60
78%
12
3
Ipamorelin
$6.69
77%
5
4
Retatrutide
$7.43
76%
12
5
Mazdutide
$16.50
63%
5
6
Melanotan II
$4.27
46%
4
7
Tesamorelin
$7.00
44%
5
8
BPC-157
$7.57
38%
12
9
Survodutide
$16.01
37%
4
10
CJC-1295
$6.69
28%
7
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 Mar 2025: 59%20 Mar 2025: 60%5 May 2025: 59%5 May 2025: 59%6 May 2025: 57%6 May 2025: 58%6 May 2025: 58%6 May 2025: 58%6 May 2025: 57%6 May 2025: 56%7 May 2025: 57%7 May 2025: 57%7 May 2025: 57%7 May 2025: 57%7 May 2025: 56%7 May 2025: 57%14 May 2025: 48%20 May 2025: 48%20 May 2025: 47%20 May 2025: 47%20 May 2025: 47%21 May 2025: 46%21 May 2025: 46%21 May 2025: 45%21 May 2025: 45%24 Jul 2025: 48%24 Jul 2025: 47%5 Aug 2025: 47%14 Aug 2025: 48%16 Aug 2025: 48%16 Dec 2025: 48%9 Jan 2026: 50%26 Jan 2026: 51%4 Feb 2026: 52%4 Feb 2026: 53%18 Feb 2026: 53%22 Feb 2026: 54%9 Apr 2026: 55%23 Apr 2026: 55%11 May 2026: 55%9 Aug 2026: current 59%59%48%59%Mar 25Aug 26
Skye Peptides test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
11 May 2026Pass
Tirzepatide
lab nameView COA
23 Apr 2026Fail
Retatrutide
lab nameView COA
9 Apr 2026Pass
Retatrutide
lab nameView COA
22 Feb 2026Pass
BPC-157
lab nameView COA
18 Feb 2026Pass
Tirzepatide
lab nameView COA
4 Feb 2026Pass
Ipamorelin
lab nameView COA
4 Feb 2026Pass
Tesamorelin
lab nameView COA
26 Jan 2026Pass
Tirzepatide
lab nameView COA
9 Jan 2026Fail
Tesamorelin
lab nameView COA
16 Dec 2025Fail
BPC-157
lab nameView COA
1-10 of 75

About Skye Peptides test results from Finnrick

Skye Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 10 peptides and 75 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Skye Peptides peptides in this dataset are Semaglutide (9 tests) and Melanotan II (4 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 75 recent tests.

Corrections
No corrections.